Login
Companies $AORT
$18.47 +$0.00 (0.0%) After hours
ARTIVION, INC. logo

ARTIVION, INC.

artivion.com

What Do They Do?

Sells aortic repair devices, heart valves and preserved human tissues to cardiac and vascular surgeons and hospitals.

How Do They Make Money?

Customers pay for medical devices when they ship and for preservation services when tissue ships; consignment product sales are charged when Artivion is notified of implantation.

revenue
SegmentShareRevenue
Aortic stent grafts
Sold outright

36%
FY2022: 30%
On-X
Sold outright

23%
FY2022: 20%
Surgical sealants
Sold outright

17%
FY2022: 21%
Other
Sold outright
1.8%
FY2022: 2.7%
Preservation services
Sold outright

22%
FY2022: 27%

Who Are Their Customers?

In the US and Canada, Artivion markets to physicians and sells through its direct sales team to hospitals and other healthcare facilities. In EMEA, it sells directly in some countries and through distributors in others; in APAC and Latin America, it uses distributors and subsidiaries, with direct sales also in Brazil.

Do Revenues Turn Into Profits?

Yes. It kept 2 cents of every revenue dollar as net income in FY2025.

Operating income, FY2025
8% of revenue
▼ −13% vs FY2024 ($38.9M, 10%)
Net income, FY2025
2% of revenue
▲ Turned profitable vs FY2024 (−$13.4M, −3%)
Free cash flow, FY2025
0% of revenue
▼ −92% vs FY2024 ($11M, 3%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +9%
vs $113.4M in Q3 FY2025
Net income
▼ Turned to a loss
vs $6.5M in Q3 FY2025
Aortic stent grafts share of revenue vs 34.9% in Q3 FY2025
  • Aug 6, 2026 Completed the Endospan acquisition Artivion also reiterated 2026 revenue guidance of $480 to $496 million and adjusted EBITDA guidance of $92 to $99 million.
  • May 7, 2026 Lowered 2026 revenue and adjusted EBITDA guidance Revenue guidance fell to $480 to $496 million from $486 to $504 million; adjusted EBITDA guidance fell to $100 to $107 million from $105 to $110 million.

Growing. Revenue grew 48% in 4 years, from $298.8M in FY2021 to $441.3M in FY2025, about 10% a year.

CardioGenesis and PerClot The older report listed CardioGenesis and PerClot among its products; the latest says CardioGenesis was abandoned and PerClot is manufactured and supplied under a transitional agreement.

Revenue over time
Aortic stent grafts On-X Surgical sealants Other Preservation services Aortic Stents And Stent Grafts
$500M$250M$0

Who Do They Compete With?

Competes with Abbott Laboratories, Medtronic, Corcym, and Terumo

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support